Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
9.61
-0.13 (-1.33%)
At close: Dec 5, 2025, 4:00 PM EST
9.60
-0.01 (-0.10%)
After-hours: Dec 5, 2025, 7:49 PM EST
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $13.78M in the quarter ending September 30, 2025, with 51.27% growth. This brings the company's revenue in the last twelve months to $57.53M, up 33.52% year-over-year. In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth.
Revenue (ttm)
$57.53M
Revenue Growth
+33.52%
P/S Ratio
17.51
Revenue / Employee
$142,749
Employees
403
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NTLA News
- 21 hours ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - The Short List — Top 10 Most Shorted Stocks Right Now - Benzinga
- 21 days ago - 2 Beaten-Down Stocks to Avoid Right Now - The Motley Fool
- 25 days ago - Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - GlobeNewsWire
- 27 days ago - Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - GlobeNewsWire
- 4 weeks ago - 2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street - The Motley Fool
- 4 weeks ago - Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% - The Motley Fool